Demographic, histologic, and prognostic characteristics for all clinical trial patients, those with EBER-ISH tumor specimens, and those with pretreatment plasma specimens, with comparison of baseline characteristics by pretreatment plasma EBV status
| . | All eligible clinical trial patients (n = 794) . | EBER-ISH patients (n = 315) . | Pretreatment plasma patients (n = 274) . | Pretreatment plasma EBV(+) (n = 54) . | Pretreatment plasma EBV(-) (n = 220) . | P value . |
|---|---|---|---|---|---|---|
| Median age (range) | 32 (16-83) | 31 (17-82) | 34 (16-83) | 36 (18-83) | 34 (16-73) | .24 |
| Ethnicity | ||||||
| Hispanic | 30 (4%) | 11 (3%) | 8 (3%) | 4 (7%) | 4 (2%) | .07* |
| White | 643 (81%) | 262 (83%) | 227 (83%) | 45 (83%) | 182 (83%) | |
| Black | 63 (8%) | 20 (6%) | 14 (5%) | 2 (4%) | 12 (5%) | |
| Other | 24 (3%) | 12 (4%) | 7 (2%) | 1 (2%) | 6 (3%) | |
| Unknown | 34 (4%) | 10 (3%) | 18 (7%) | 2 (4%) | 16 (7%) | |
| Histology | ||||||
| Mixed cellularity | 87 (11%) | 40 (13%) | 32 (12%) | 13 (24%) | 19 (9%) | .008* |
| Nodular sclerosis | 562 (71%) | 245 (78%) | 191 (69%) | 23 (43%) | 168 (76%) | <.0001* |
| Lymphocyte-rich | 14 (2%) | 8 (3%) | 4 (1.5%) | 2 (4%) | 2 (1%) | |
| Lymphocyte-depleted | 2 (0.2%) | 1 (0.3%) | 1 (0.4%) | 1 (2%) | 0 (0%) | |
| cHL, not further classifiable | 100 (13%) | 20 (6%) | 37 (14%) | 13 (24%) | 24 (11%) | .02* |
| Unknown | 29 (4%) | 1 (0.3%) | 9 (3%) | 2 (4%) | 7 (3%) | |
| Age ≥45 | 146 (18%) | 51 (16%) | 61 (22%) | 16 (30%) | 45 (20%) | .15 |
| Male gender | 414 (52%) | 176 (56%) | 154 (56%) | 36 (67%) | 118 (54%) | .09 |
| Stage IV | 201 (25%) | 78 (25%) | 82 (30%) | 19 (35%) | 63 (29%) | .41 |
| Albumin < 4 g/dL | 532 (67%) | 207 (66%) | 185 (68%) | 36 (67%) | 149 (68%) | .87 |
| Hemoglobin < 10.5 g/dL | 140 (18%) | 47 (15%) | 52 (19%) | 13 (24%) | 39 (18%) | .33 |
| Leukocytes ≥ 15 000 WBCs/mm3 | 104 (13%) | 44 (14%) | 45 (16%) | 3 (6%) | 42 (19%) | .01 |
| Lymphocytes < 600/mm3 or < 8% WBCs | 163 (21%) | 62 (20%) | 62 (23%) | 11 (20%) | 51 (23%) | .72 |
| . | All eligible clinical trial patients (n = 794) . | EBER-ISH patients (n = 315) . | Pretreatment plasma patients (n = 274) . | Pretreatment plasma EBV(+) (n = 54) . | Pretreatment plasma EBV(-) (n = 220) . | P value . |
|---|---|---|---|---|---|---|
| Median age (range) | 32 (16-83) | 31 (17-82) | 34 (16-83) | 36 (18-83) | 34 (16-73) | .24 |
| Ethnicity | ||||||
| Hispanic | 30 (4%) | 11 (3%) | 8 (3%) | 4 (7%) | 4 (2%) | .07* |
| White | 643 (81%) | 262 (83%) | 227 (83%) | 45 (83%) | 182 (83%) | |
| Black | 63 (8%) | 20 (6%) | 14 (5%) | 2 (4%) | 12 (5%) | |
| Other | 24 (3%) | 12 (4%) | 7 (2%) | 1 (2%) | 6 (3%) | |
| Unknown | 34 (4%) | 10 (3%) | 18 (7%) | 2 (4%) | 16 (7%) | |
| Histology | ||||||
| Mixed cellularity | 87 (11%) | 40 (13%) | 32 (12%) | 13 (24%) | 19 (9%) | .008* |
| Nodular sclerosis | 562 (71%) | 245 (78%) | 191 (69%) | 23 (43%) | 168 (76%) | <.0001* |
| Lymphocyte-rich | 14 (2%) | 8 (3%) | 4 (1.5%) | 2 (4%) | 2 (1%) | |
| Lymphocyte-depleted | 2 (0.2%) | 1 (0.3%) | 1 (0.4%) | 1 (2%) | 0 (0%) | |
| cHL, not further classifiable | 100 (13%) | 20 (6%) | 37 (14%) | 13 (24%) | 24 (11%) | .02* |
| Unknown | 29 (4%) | 1 (0.3%) | 9 (3%) | 2 (4%) | 7 (3%) | |
| Age ≥45 | 146 (18%) | 51 (16%) | 61 (22%) | 16 (30%) | 45 (20%) | .15 |
| Male gender | 414 (52%) | 176 (56%) | 154 (56%) | 36 (67%) | 118 (54%) | .09 |
| Stage IV | 201 (25%) | 78 (25%) | 82 (30%) | 19 (35%) | 63 (29%) | .41 |
| Albumin < 4 g/dL | 532 (67%) | 207 (66%) | 185 (68%) | 36 (67%) | 149 (68%) | .87 |
| Hemoglobin < 10.5 g/dL | 140 (18%) | 47 (15%) | 52 (19%) | 13 (24%) | 39 (18%) | .33 |
| Leukocytes ≥ 15 000 WBCs/mm3 | 104 (13%) | 44 (14%) | 45 (16%) | 3 (6%) | 42 (19%) | .01 |
| Lymphocytes < 600/mm3 or < 8% WBCs | 163 (21%) | 62 (20%) | 62 (23%) | 11 (20%) | 51 (23%) | .72 |
cHL, classical Hodgkin lymphoma; WBC, white blood cell.
P values denoted with an asterisk (*) were from Fisher’s exact test comparing proportion of the category of interest between plasma EBV(+) and plasma EBV(-) patients by combining other categories.